This study is about pancreatic cancer. If the diagnostic cancer is done at an early stage (\<2cm), the chances of recovery are very good. But the main problem is there is not any detections means for this cancer. Sadly, when there is a cancer diagnostic , it's already too late in the majority of cases, because the cancer is in an advanced case. Today, there is no any effective means of detection... Blood markers can be a simple means of early detection
The purpose of this study is to establish a sero-library in a case-control cohort to assess several potentially useful serum biomarkers, such as adiponectin in the early diagnosis of pancreatic cancer.
Study Type
OBSERVATIONAL
Enrollment
400
Blood sample will be performed
CHU Saint-Etienne
Saint-Etienne, France
RECRUITINGInstitut Cancérologique Lucien Newirth (ICLN)
Saint-Priest-en-Jarez, France
RECRUITINGSerum adiponectin concentration
Measure by blood sample result Serum adiponectin concentration threshold for which the specificity will be 100% for the diagnosis of pancreatic cancer with a sensitivity of 80%.
Time frame: Months : 0
Serum CA19.9 concentration
Measure by blood sample result Threshold for Comparison of diagnostic performance compared to serum adiponectin concentration
Time frame: Months : 0, 3, 6, 9, 12
Tumor response and progression rates according to RECIST v1.1
Tumor response and progression rates defined according to RECIST v1.1 criteria according to a serum threshold of the prognostic biomarker to be identified by logistic regression analyzes.
Time frame: Month 12
Progression-free survival
Time frame: Months : 24
Overall survival
Time frame: Months : 24
Serum adiponectin concentration
Measure by blood sample result Serum adiponectin concentration to correlate with cancer progression or not.
Time frame: Months : 3, 6, 9, 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.